Canonical (CD74/CD44) and Non-Canonical (CXCR2, 4 and 7) MIF Receptors Are Differentially Expressed in Rheumatoid Arthritis Patients Evaluated by DAS28-ESR

Sánchez-Zuno, Gabriela Athziri; Bucala, Richard; Hernández‐Bello, Jorge; Román-Fernández, Ilce Valeria; García‐Chagollán, Mariel; Nicoletti, Ferdinando; Matuz-Flores, Mónica Guadalupe; García‐Arellano, Samuel; Esparza-Michel, Judith Alejandra; Cerpa-Cruz, Sergio; Pérez-Guerrero, Edsaúl Emilio; Muñoz‐Valle, José Francisco

doi:10.3390/jcm11010120

Cited by 12 publications

(7 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A high expression of MIF mRNA and protein in human autoimmune-associated kidney disease was described over 20 years ago by Lan et al [65]. Both CD74 and MIF have been extensively studied in the context of rheumatoid arthritis, and MIF is now recognized as a crucial player in the development of this disease [66][67][68][69]. Recently, therapeutics aimed at disrupting MIF and/or CD74 binding have been considered in the treatment of several autoimmune diseases [64,70,71].…”

Section: A Brief Overview Of Mif and Cd74mentioning

confidence: 99%

MIF and CD74 as Emerging Biomarkers for Immune Checkpoint Blockade Therapy

Fey,

Nichols,

Tran

et al. 2024

Cancers

View full text Add to dashboard Cite

Immune checkpoint blockade (ICB) therapy is used to treat a wide range of cancers; however, some patients are at risk of developing treatment resistance and/or immune-related adverse events (irAEs). Thus, there is a great need for the identification of reliable predictive biomarkers for response and toxicity. The cytokine MIF (macrophage migration inhibitory factor) and its cognate receptor CD74 are intimately connected with cancer progression and have previously been proposed as prognostic biomarkers for patient outcome in various cancers, including solid tumors such as malignant melanoma. Here, we assess their potential as predictive biomarkers for response to ICB therapy and irAE development. We provide a brief overview of their function and roles in the context of cancer and autoimmune disease. We also review the evidence showing that MIF and CD74 may be of use as predictive biomarkers of patient response to ICB therapy and irAE development. We also highlight that careful consideration is required when assessing the potential of serum MIF levels as a biomarker due to its reported circadian expression in human plasma. Finally, we suggest future directions for the establishment of MIF and CD74 as predictive biomarkers for ICB therapy and irAE development to guide further research in this field.

show abstract

Section: A Brief Overview Of Mif and Cd74mentioning

confidence: 99%

MIF and CD74 as Emerging Biomarkers for Immune Checkpoint Blockade Therapy

Fey,

Nichols,

Tran

et al. 2024

Cancers

View full text Add to dashboard Cite

show abstract

“…In addition, CD74 and NOTCH3 exhibited the highest positive or negative correlation with HLA-DRB1/DMB, respectively. CD74 is a membrane protein mainly distributed on the surface of immune cells, which transduces signals by binding to MIF (Sánchez-Zuno et al, 2021), while HLA-DRB1 sharesepitope sequences that mainly encode antigen presentation proteins and contribute to ACPA-positive RA (Kampstra and Toes, 2017). The positive correlation between the two may reflect the degree of immune cell-mediated autoimmune inflammation.…”

Section: Figure 10mentioning

confidence: 99%

Identification of immunological characterization and Anoikis-related molecular clusters in rheumatoid arthritis

Zhao,

Wei,

Shi

et al. 2023

Front. Mol. Biosci.

View full text Add to dashboard Cite

Objective: To investigate the potential association between Anoikis-related genes, which are responsible for preventing abnormal cellular proliferation, and rheumatoid arthritis (RA).Methods: Datasets GSE89408, GSE198520, and GSE97165 were obtained from the GEO with 282 RA patients and 28 healthy controls. We performed differential analysis of all genes and HLA genes. We performed a protein-protein interaction network analysis and identified hub genes based on STRING and cytoscape. Consistent clustering was performed with subgrouping of the disease. SsGSEA were used to calculate immune cell infiltration. Spearman’s correlation analysis was employed to identify correlations. Enrichment scores of the GO and KEGG were calculated with the ssGSEA algorithm. The WGCNA and the DGIdb database were used to mine hub genes’ interactions with drugs.Results: There were 26 differentially expressed Anoikis-related genes (FDR = 0.05, log2FC = 1) and HLA genes exhibited differential expression (P < 0.05) between the disease and control groups. Protein-protein interaction was observed among differentially expressed genes, and the correlation between PIM2 and RAC2 was found to be the highest; There were significant differences in the degree of immune cell infiltration between most of the immune cell types in the disease group and normal controls (P < 0.05). Anoikis-related genes were highly correlated with HLA genes. Based on the expression of Anoikis-related genes, RA patients were divided into two disease subtypes (cluster1 and cluster2). There were 59 differentially expressed Anoikis-related genes found, which exhibited significant differences in functional enrichment, immune cell infiltration degree, and HLA gene expression (P < 0.05). Cluster2 had significantly higher levels in all aspects than cluster1 did. The co-expression network analysis showed that cluster1 had 51 hub differentially expressed genes and cluster2 had 72 hub differentially expressed genes. Among them, three hub genes of cluster1 were interconnected with 187 drugs, and five hub genes of cluster2 were interconnected with 57 drugs.Conclusion: Our study identified a link between Anoikis-related genes and RA, and two distinct subtypes of RA were determined based on Anoikis-related gene expression. Notably, cluster2 may represent a more severe state of RA.

show abstract

“…Alternatively, MIF ligation of CD74 can lead to regulated intramembrane proteolysis (RIP) and the release of an intracellular domain (ICD) of CD74 that has a nuclear trafficking capacity, acts as a transcription factor, and can activate NF‐κB 138–141 . In turn, the liberated soluble CD74 ectodomain has been found to serve as a circulating scavenger to neutralize MIF‐elicited signaling responses and its plasma levels have been (inversely) associated with disease progression 118,119,142–145 . How soluble CD74 regulates MIF‐2 activity is poorly understood, but initial studies have observed correlations between soluble CD74 plasma levels and disease activity in burn and cardiac surgery patients 145,146 .…”

Section: Receptors and Signaling Pathways Instigated By Mif‐2 And Com...mentioning

confidence: 99%

“…[138][139][140][141] In turn, the liberated soluble CD74 ectodomain has been found to serve as a circulating scavenger to neutralize MIF-elicited signaling responses and its plasma levels have been (inversely) associated with disease progression. 118,119,[142][143][144][145] How soluble CD74 regulates MIF-2 activity is poorly understood, but initial studies have observed correlations between soluble CD74 plasma levels and disease activity in burn and cardiac surgery patients. 145,146 The cardio-and hepatoprotective activities of the MIF/CD74 axis in the ischemic heart and during hepatic fibrosis, respectively, involve signaling through the metabolic stress enzyme AMP-activated protein kinase (AMPK) as well as Jun kinase (JNK) pathways.…”

Section: Pathways Instigated By Mif-2 and Comparison To Mifmentioning

confidence: 99%

D‐dopachrome tautomerase in cardiovascular and inflammatory diseases—A new kid on the block or just another MIF?

et al. 2022

View full text Add to dashboard Cite

Macrophage migration inhibitory factor (MIF) as well as its more recently described structural homolog D‐dopachrome tautomerase (D‐DT), now also termed MIF‐2, are atypical cytokines and chemokines with key roles in host immunity. They also have an important pathogenic role in acute and chronic inflammatory conditions, cardiovascular diseases, lung diseases, adipose tissue inflammation, and cancer. Although our mechanistic understanding of MIF‐2 is relatively limited compared to the extensive body of evidence available for MIF, emerging data suggests that MIF‐2 is not only a functional phenocopy of MIF, but may have differential or even oppositional activities, depending on the disease and context. In this review, we summarize and discuss the similarities and differences between MIF and MIF‐2, with a focus on their structures, receptors, signaling pathways, and their roles in diseases. While mainly covering the roles of the MIF homologs in cardiovascular, inflammatory, autoimmune, and metabolic diseases, we also discuss their involvement in cancer, sepsis, and chronic obstructive lung disease (COPD). A particular emphasis is laid upon potential mechanistic explanations for synergistic or cooperative activities of the MIF homologs in cancer, myocardial diseases, and COPD as opposed to emerging disparate or antagonistic activities in adipose tissue inflammation, metabolic diseases, and atherosclerosis. Lastly, we discuss potential future opportunities of jointly targeting MIF and MIF‐2 in certain diseases, whereas precision targeting of only one homolog might be preferable in other conditions. Together, this article provides an update of the mechanisms and future therapeutic avenues of human MIF proteins with a focus on their emerging, surprisingly disparate activities, suggesting that MIF‐2 displays a variety of activities that are distinct from those of MIF.

show abstract

Canonical (CD74/CD44) and Non-Canonical (CXCR2, 4 and 7) MIF Receptors Are Differentially Expressed in Rheumatoid Arthritis Patients Evaluated by DAS28-ESR

Cited by 12 publications

References 31 publications

MIF and CD74 as Emerging Biomarkers for Immune Checkpoint Blockade Therapy

MIF and CD74 as Emerging Biomarkers for Immune Checkpoint Blockade Therapy

Identification of immunological characterization and Anoikis-related molecular clusters in rheumatoid arthritis

D‐dopachrome tautomerase in cardiovascular and inflammatory diseases—A new kid on the block or just another MIF?

Contact Info

Product

Resources

About